The economic implications of the use of anti-vascular endothelial growth factor drugs in age-related macular degeneration

Azad, Rajvardhan; Chandra, Parijat; Gupta, Ritesh
November 2007
Indian Journal of Ophthalmology;Nov2007, Vol. 55 Issue 6, p441
Academic Journal
No abstract available.


Related Articles

  • Retreatment with Anti-VEGF After Stabilization of AMD.  // Review of Ophthalmology;Oct2012, Vol. 19 Issue 10, p80 

    The article informs that retreatment with anti-vascular endothelial growth factor (VEGF) is required for patients with neo-vascular age-related macular degeneration after a year of the drug Bevacizumab administration.

  • Judicious use of anti-VEGF agents advised as 'reasonable'. Reichel, Elias // Ocular Surgery News;3/10/2011, Vol. 29 Issue 5, p18 

    The article reports on the reasonable advice on the judicious use of anti-vascular endothelial growth factors (VEGF) agents for age-related macular degeneration (AMD) treatment.

  • 2002: Specialists pleased with ongoing retinal progress. Charters, Lynda // Ophthalmology Times;12/1/2002, Vol. 27 Issue 23, p28 

    Reports on advances in therapies for various types of retinal diseases. Anti-vascular endothelial growth factor drugs for age-related macular degeneration; Intravitreal steroids for cystoid macular edema; Radial optic neurotomy for retinal vein occlusions. INSET: Take-Home Message.

  • Avastin versus Lucentis. Godlee, Fiona // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;5/5/2012, Vol. 344 Issue 7855, preceding p1 

    An introduction is presented in which the editor-in-chief discusses articles within the issue on topics such as anti-vascular endothelial growth factors, manufacturers discouraging the use of anti-cancer drug, bevacizumab for macular degeneration.

  • Intravitreal anti-VEGF drugs are step forward in AMD management. Charters, Lynda // Ophthalmology Times;12/15/2005, Vol. 30 Issue 24, p1 

    The article reports on the success of the development of the anti-vascular endothelial growth factor treatments for age-related macular degeneration (AMD). According to retina specialist Charles Schepens, the introduction of pegaptanib sodium and the clinical trial data of ranibizumab indicated...

  • Don't Veg Out with VEGF.  // Review of Optometry;8/15/2008, Vol. 145 Issue 8, p89 

    The article provides an answer to a question on the optometrist role in comanaging patients undergoing anti-vascular endothelial growth factor injections for age-related macular degeneration.

  • Vitreomacular interface affects anti-VEGF injection intervals for AMD. Ahem, Steve; Hasson, Matt // Ocular Surgery News;4/25/2014, Vol. 32 Issue 8, p17 

    The article discusses a study which shows that anti-vascular endothelial growth factor (VEGF) injection intervals for the management of age-related macular degeneration is affected by vitreomacular interface disease.

  • Exploring anti-VEGF therapy for wet AMD: What dosing strategy is best? Boyle, Erin L.; Harcharek, Alexandra; Hasson, Matt; Hsvidas, Cara; Nale, Patricia; Master, Joseph; Pagnani, Michelle; Preston, Courtney // Ocular Surgery News;2/25/2011, Vol. 29 Issue 4, p22 

    The article offers insights from doctor Philip J. Rosenfeld regarding the best dosing strategy for studying anti-vascular endothelial growth factors (VEGF) therapy for wet age-related macular degeneration (AMD).

  • Identification of ORT after anti-VEGF treatment for neovascular AMD critical.  // Ocular Surgery News;11/25/2014, Vol. 32 Issue 22, p34 

    The article reports on a study published in the journal "Ophthalmology" that reveals the importance of identification of eyes with outer retinal tubulations after anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration.

  • CATT provides reassuring data on anti-VEGF use, but some Questions remain.  // Ocular Surgery News;1/25/2012, Vol. 30 Issue 2, Special section p11 

    The article reports that the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) offers reassuring data on anti-vascular endothelial growth factor (VEGF) use but another year of investigation in necessary to draw more definitive conclusions according to physician Neil M....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics